☀️     🌓

Prescribing Advice for GPs

An NHS Prescribing Advisers' Blog

SMC Update - August 2011

The Scottish Medicines Consortium (SMC) has issued its monthly advice on new medicines.

Calcium carbonate and cholecalciferol (Kalcipos-D®) has been accepted for the prevention and treatment of calcium and vitamin D deficiency in the elderly and in addition to specific osteoporosis treatment of patients who are at risk of deficiency.

Darunavir (Prezista®) has been accepted for the treatment of HIV-1 infection in combination with low dose ritonavir.

Glucosamine sulphate (Dolenio®) has been rejected for symptomatic treatment of mild to moderate osteoarthritis of the knee. The manufacturer failed to make a submission.

Glucosamine sulphate (Glusartel®) has been rejected for relief of symptoms in mild to moderate osteoarthritis of the knee. The manufacturer failed to present a sufficiently robust economic case to gain acceptance.

Methotrexate 50mg/ml solution for injection (Metoject®) has been accepted for the treatment of polyarthritic forms of severe active juvenile idiopathic arthritis. It is an option for patients when the response to non-steroidal anti-inflammatory drugs has been inadequate, a disease modifying drug is indicated and parenteral administration of methotrexate is appropriate.

Action: Clinicians should be aware of the recommendations of the SMC. Routine use of rejected and restricted medicines should be avoided.

Share 'SMC Update - August 2011' by emailShare 'SMC Update - August 2011' on FacebookShare 'SMC Update - August 2011' on TwitterShare 'SMC Update - August 2011' on MastodonShare 'SMC Update - August 2011' on LinkedInShare 'SMC Update - August 2011' on reddit

atomic-wealth

No Comments to “SMC Update - August 2011”

Leave a Comment

Your email address will not be published. Required fields are marked *

Please be aware that you comment is subject to our Privacy Policy.

This site uses Akismet to reduce spam. Learn how your comment data is processed.

Prescribing Advice for GPs is powered by ClassicPress.
Connect to our RSS or Atom Feeds.